Questioning the role of HIPEC in patients with granulosa cell ovarian tumours
2024
Questioning the role of HIPEC in granulosa cell ovarian tumours
Sample size: 28
Commentary
Author Information
Author(s): Iavazzo Christos, Gkegkes Ioannis D.
Primary Institution: Gynaecological Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece
Conclusion
The authors seek clarification on the use of HIPEC agents and the effectiveness of adjuvant chemotherapy for granulosa cell tumours.
Supporting Evidence
- Less than 50% of patients had disease recurrence after CRS/HIPEC.
- HIPEC can provide loco-regional disease control in rare ovarian tumours.
- Data from Germany do not support the use of adjuvant chemotherapy in early and advanced stages of adult granulosa cell tumours.
- A recent study showed no benefit from adjuvant therapy following complete CRS for granulosa cell tumour relapse.
Takeaway
This letter questions how effective a treatment called HIPEC is for a rare type of ovarian cancer and asks for more information about the treatment used.
Limitations
No information is provided regarding adjuvant chemotherapy and the site of first recurrence.
Participant Demographics
Three out of 28 patients were aged 51 to 76 years with a PCI score from 5 to 21.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website